17-20 June 2015 Lugano
7-OT | CHRONOS-1: Phase II trial of intravenous PI3K-&945;/-&946; inhibitor copanlisib in patients with relapsed/refractory indolent non-Hodgkins lymphoma | Martin Dreyling | Received |
8-OT | Design of a Phase 1/2, open-label, dose-escalation trial of the Toll-like receptor antagonist IMO-8400 in patients with MYD88 L265P-positive diffuse large B-cell lymphoma | James Baker | Received |
9-OT | Ibrutinib in combination with Rituximab for Relapsed Mantle Cell Lymphoma: An Update from a Phase II Clinical Trial | Michael Wang | Received |
10-OT | Efficacy and Safety of Lenalidomide and Rituximab vs Placebo and Rituximab in a Phase 3 Trial in Relapsed/Refractory Non-Hodgkin Lymphoma | Rachel Sopko | Received |
11-OT | FIL-VERAL12: phase II randomized study with Rituximab-DHAP /- Bortezomib as induction in young relapsed/refractory Diffuse Large B-cell Lymphoma eligible to transplant. | ANNALISA CHIAPPELLA | Received |
13-OT | The Elderly Project by the Fondazione Italiana Linfomi (FIL): A Prospective Multidimensional Assessment of Eldelry Patients with Diffuse Large B-Cell Lymphoma. | Francesco Merli | Received |
14-OT | CLLR3 A randomized Phase II trial evaluating the chemotherapies FC/ B combined with GA101 followed by GA101 maintenance in relapsed/ refractory CLL | Nadine Kutsch | Received |
151-P | T-cell subpopulations quantified by flow cytometry in lymph node cell suspensions identify a group of patients with follicular lymphoma with favorable outcome | Laura Magnano Mayer | Received |
154-P | NR4A3 suppresses lymphomagenesis by induction of apoptosis and serves as a drug target for lymphoma therapy | Alexander Deutsch | Received |
157-P | Prognostic impact of cell of origin profile in young patients with high risk diffuse large B cell lymphoma: results of the BIO-DLCL04 trial of Fondazione Italiana Linfomi | ANNALISA CHIAPPELLA | Received |
158-P | Cell of origin is not associated with survival after DLBCL relapse | Umar Farooq | Received |
159-P | Impact on survival of MYC genetic alterations but not MYD88L265P mutation in primary testicular DLBCL | Alexandra Valera | Received |
160-P | MYD88 L265P mutations, but not other variants, identify a subgroup of patients with ABC diffuse large B-cell lymphoma, extranodal involvement and poor outcome | JORDINA ROVIRA | Received |
161-P | MYC or BCL2 copy number aberration is a strong predictor of outcome in patients with diffuse large B-cell lymphoma | Ting-Xun Lu | Received |
162-P | Analysis of double-hit lymphoma cases by genetic subtype | Daniel Landsburg | Received |
163-P | Molecular characterization of diffuse large B-cell lymphoma recurrences: clonal relationship and different modes of tumor evolution | Darius Juskevicius | Received |
164-P | Relapsed DLBCLs present frequent copy number variations of genes involved in lymphomagenesis with different pattern between early- and late-relapsed DLBCLs | BROSÉUS Julien | Received |
166-P | Prognostic Significance of Genomic Alterations in Mantle Cell Lymphoma | Kurt Bantilan | Received |
168-P | PRIMA-1Met induces myeloma and mantle cell lymphoma cell death, by impairing ROS/GSH balance. | Benoit Tessoulin | Received |
169-P | Chronic Lymphocytic Leukemia B-cells are rescued from apoptosis by extracellular vesicles from bone marrow mesenchymal stromal cells | Emerence Crompot | Received |
170-P | Prognostic significance of TET and IDH mRNA expression in chronic lymphocytic leukemia | Michal Van Damme | Received |
171-P | Optimal Treatment Strategies for Early-Stage Hodgkins Lymphoma with B Symptoms and Bulky Disease at Presentation | Jay Reddy | Received |
172-P | Infradiaphragmatic Hodgkin Lymphoma: long term outcome improved by chemotherapy-radiotherapy VS chemotherapy alone. | cédric rossi | Received |
173-P | Consolidation radiation after ABVD is effective treatment for ed patients with Hodgkins lymphoma (HL) with interim PET positive scans. | Noelle ORourke | Received |
174-P | Pencil Beam Scanning Proton Therapy for Lymphoma Patients with Mediastinal Involvement: A Dosimetric Study and Preliminary Clinical Data | Katerina Dedeckova | Received |
175-P | Cardiac Radiation Dose and Predicted Cardiac Mortality in the UK RAPID Trial in Early Stage Hodgkin Lymphoma | David Cutter | Received |
176-P | Evaluation of the risk of relapse in classical Hodgkin lymphoma at event-free time points and survival comparison to the general population in British Columbia. | Greg Hapgood | Received |
177-P | Healthcare utilization in the AETHERA trial: phase 3 study of brentuximab vedotin in patients at increased risk of residual Hodgkin lymphoma post ASCT | vijayveer bonthapally | Received |
179-P | Hodgkin Lymphoma Post-Transplant Lymphoproliferative Disorder (HL-PTLD): A Comparative Analysis of Prognosis and Survival | Andrew Evens | Received |
181-P | First in-patient proof of safety and efficacy of a 4th generation chimeric antigen receptor-modified T cells for the treatment of R/R CD30-positive lymphoma | Zhitao Ying | Received |
182-P | Chronic lymphocytic leukaemia treatment and outcome in the UKs population-based Haematological Malignancy Research Network | Russell Patmore | Received |
183-P | Response to rituximab in B-CLL patients is adversely impacted by frequency of IL-10 competent B-CLL cells and FCGR3A polymorphism. A study of FCGCLL/MW and GOELAMS groups. | Anne-laure Gagez | Received |
184-P | Results of a Phase II randomizing intensified rituximab pre-phase followed by standard FCR vs standard FCR in previously untreated patients with Active B-CLL. | Stephane Lepretre | Received |
185-P | A Randomised Study of F(C)R in Fit, Elderly Patients with Chronic Lymphocytic Leukaemia (CLL) shows high response rates and a dose intensity effect | Stephen Mulligan | Received |
186-P | Targeting Mutated BRAF with Vemurafenib is Safe and Highly Active in Relapsed/Refractory Hairy Cell Leukemia: a Phase-2 Italian Clinical Trial (HCL-PG01) | Enrico Tiacci | Received |
187-P | The clinical course of patients with follicular lymphoma in the rituximab era | inas el-najjar | Received |
188-P | Event-free Survival at 12 Months and Subsequent Overall Survival in Patients with Follicular Lymphoma Managed in the Rituximab Era | Emmanuel Bachy | Received |
189-P | Follicular lymphoma and clinical characteristics of histologic transformation | Miriam Mendez | Received |
190-P | RISK INCIDENCE OF FOLLICULAR LYMPHOMA TRANSFORMATION: MULTICENTRE RETROSPECTIVE ANALYSIS OF THE SPANISH GELTAMO GROUP | Sara Alonso-Alvarez | Received |
191-P | Comparison of lenalidomide and rituximab with chemoimmunotherapy in patients with untreated grade 1-2 follicular lymphoma treated at the MD Anderson Cancer Center | Chan Yoon Cheah | Received |
192-P | Extended Dosing Lenalidomide with Intensified Rituximab in Untreated Indolent NHL | Nathan Fowler | Received |
196-P | Rituximab Maintenance (MR) improves PFS and OS in all Patients (pts) with Follicular Lymphoma (FL) - Individual Patient Data (IPD) meta-analysis | Liat Vidal-Fisher | Received |
199-P | Higher risk of rituximab intolerance in patients with Waldenstrm Macroglobulinemia | Jorge Castillo | Received |
201-P | Outcomes in Kaposi sarcoma herpesvirus-associated multicentric Castleman disease patients treated with rituximab and liposomal doxorubicin (R-Dox) | Thomas Uldrick | Received |
202-P | Association between quality of response and outcomes in patients with newly diagnosed mantle cell lymphoma receiving VR-CAP vs R-CHOP in the phase 3 LYM-3002 study | Gregor Verhoef | Received |
204-P | Clinical, metabolic and molecular responses with sequential R-CHOP, high-dose cytarabine, and iodine-131 tositumomab-based transplant in Mantle Cell Lymphoma | Kurt Bantilan | Received |
205-P | Multi-center phase II study with lenalidomide plus rituximab as initial treatment for mantle cell lymphoma: survival update and health-related quality-of-life analysis | Jia Ruan | Received |
207-P | Poor Overall Survival of Patients with Ibrutinib-Resistant Mantle Cell Lymphoma | Peter Martin | Received |
209-P | High Dose Sequential Chemotherapy with Rituximab and ASCT as First Line Therapy in Adult MCL Patients: Clinical and Molecular Response of the MCL0208 Trial, a FIL Study. | Sergio Cortelazzo | Received |
210-P | The standard, revised and a simplified International Prognostic Index reliably predict outcome in patients with PET/CT-staged DLBCL treated with R-CHOP | Diego Villa | Received |
211-P | Female patients with DLBCL and involvement of the reproductive organs have poor outcomes and markedly increased risk of CNS relapse with R-CHOP(-like) therapy | Tarec Christoffer El-Galaly | Received |
212-P | Evaluation of the site of central nervous system (CNS) relapse in patients with Diffuse Large B-cell lymphoma (DLBCL) by the CNS risk model | Roopesh Kansara | Received |
213-P | Clinical and Treatment-Related Features Determining the Risk of Late Relapse in Patients with Diffuse Large B-cell Lymphoma | Lena Modvig | Received |
215-P | Spleen involvement identified on baseline PET imaging influences outcome of young patients with high risk diffuse large B cell lymphoma treated with R-CHOP14 but not R-ACVBP | Olivier Casasnovas | Received |
217-P | Vincristine omission, but not dose reduction, is associated with decreased survival in elderly DLBCL patients | Salma Afifi | Received |
218-P | Outcome analysis of diffuse large B cell lymphoma (DLBCL) in HIV-infected and immunocompetent (IC) patients: The Swiss HIV Cohort study (SHCS) | Annarita Conconi | Received |
219-P | Secondary CNS lymphoma in the rituximab-era: Data on the first 100 patients from a prospective registry | Stephan Kreher | Received |
220-P | Dose-Dense Chemoimmunotherapy and Early CNS Prophylaxis for High-Risk DLBCL Interim Results from a Nordic Phase II Study | Sirpa Lepp | Received |
221-P | Systemic high-dose methotrexate (HD-MTX) consolidation in poor-risk diffuse large B-cell lymphoma is associated with improved survival in Germinal Centre B-cell phenotype | Michael Gilbertson | Received |
222-P | The addition of Rituximab to CODOX-M & IVAC in first Line therapy of poor risk Burkitt Lymphoma (IPI 3-5) yields an excellent outcome: a Phase 2 UK NCRI/LLR Trial (LLR 04058) | andrew mcmillan | Received |
225-P | Prognostic impact of immunohistological profiling in primary CNS lymphoma | Stephan Kreher | Received |
226-P | Addition of Rituximab to the Treatment of Newly Diagnosed Primary CNS Lymphoma is Associated with Improved Outcome: A French LOC Network study | Emmanuel GYAN | Received |
227-P | BAM induction followed by autologous stem cell transplantation for patients with primary central nervous system lymphoma: a multicenter study from the Spanish group GEL-TAMO | MIRIAM LÓPEZ-PARRA | Received |
228-P | High efficiency and tolerance of Temozolomide in relapse/refractory primary vitreo-retineal lymphoma: a multicentric study from the LOC network | Sylvain Choquet | Received |
229-P | Temsirolimus for primary CNS lymphoma | Stephan Kreher | Received |
230-P | Long-Term Outcome of 490 Patients with Early-Stage Extra-nodal Marginal Zone Lymphoma | Sewit Teckie | Received |
231-P | Clinical Characteristics and Patterns of Care of Patients (pts) with Peripheral T-cell Lymphoma (PTCLs) according to age at time of diagnosis: A T-Cell Project snapshot. | Monica Bellei | Received |
232-P | Characteristics and Patterns of Care of Patients (pts) =70 years with T-cell non-Hodgkin Lymphoma (TCL) in the United States (US) | Chadi Nabhan | Received |
233-P | A large prospective multicenter study of peripheral T-cell lymphoma in Thailand: clinical, histopathology, treatment outcomes, and survival | Jakrawadee Julamanee | Received |
234-P | A proposal of a new staging systemfor extranodal natural killer T-cell lymphoma, nasal-type: a multicenter study from Chinese Southwest Oncology Group (CSWOG) and Asia Lymphoma Study Group (ALSG) | Tongyu Lin | Received |
235-P | A clinicopathological study of Lennert lymphoma and possible prognostic factors | Daisuke Kurita | Received |
236-P | SUBCUTANEOUS PANNICULITIS-LIKE T-CELL LYMPHOMA IN THAILAND: CLINICAL OUTCOMES, TREATMENTS, AND PROGNOSTIC FACTORS | Udomsak Bunworasate | Received |
237-P | Immunophenotypic heterogeneity of T-LGLL: clinical and biological implications | Renato Zambello | Received |
238-P | Breast Implant Associated Anaplastic Large cell Lymphoma: a new distinct clinicopathologic entity. | Camille Laurent | Received |
239-P | Molecular Heterogeneity of ALK-negative Anaplastic Large Cell Lymphoma | Andrew Feldman | Received |
243-P | Polyethylene glycol conjugated asparaginase-CHOP in adult newly diagnosed extranodal NK/T-cell lymphoma: a multi-center prospective phase II study | Wen Zheng | Received |
244-P | Encouraging experience in the treatment of nasal type extra-nodal NK/T-cell lymphoma in a non-Asian population | Shunan Qi | Received |
245-P | Clinical Outcome of P-Gemox for Newly Diagnosed Stage III/IV or Relapsed/Refractory ENKTL | HuiQiang Huang | Received |
247-P | The role of transplant in the treatment of Peripheral T-cell Lymphomas (PTCLs): an analysis from the T-Cell project database. | Monica Bellei | Received |
248-P | Phase II study of SMILE chemotherapy for relapsed/refractory peripheral T-cell lymphoma | Ritsuro Suzuki | Received |
249-P | Bendamustine treatment in refractory/relapsed T cell lymphomas: a retrospective multicenter study | Emilie Reboursiere | Received |
250-P | The mTORC1 Inhibitor Everolimus Produces Tumor Responses in Patients with Relapsed T-cell Non-Hodgkin Lymphoma | Thomas Witzig | Received |
252-P | Baseline metabolic tumor burden in DLBCL affects response to immuno-chemotherapy and patients outcome through influence of rituximab pharmacokinetics. A LYSA group study. | Olivier Casasnovas | Received |
254-P | Role of bone marrow biopsy (BMB) in classic Hodgkin Lymphoma (cHL) staging in FDG-PET/CT era. | benedetta puccini | Received |
255-P | Hodgkin Lymphoma: PET-CT or bone marrow biopsy? | Zeinab Abou Yehia | Received |
257-P | PROGNOSTIC VALUE OF INTERIM FDG-PET/CT IN 100 DIFFUSE LARGE B-CELL LYMPHOMA TREATED WITH R-CHOP ACCORDING TO INTERPRETATION CRITERIA AND PRETHERAPEUTIC PROGNOSTIC FACTORS | Caroline Faes | Received |
258-P | Blinded evaluation of the prognostic value of FDG-PET/CT after 2 cycles of RCHOP in DLBCL UK-NCRI study | Mikhaeel George | Received |
259-P | No survival benefit associated with routine imaging for classical Hodgkin lymphoma in complete remission: A Danish-Swedish population-based study | Tarec Christoffer El-Galaly | Received |
261-P | Biological Rational for Sequential Targeting of Bruton Tyrosine Kinase and Bcl2 to Overcome Cd40-induced BH3-mimetics Resistance in Mantle Cell Lymphoma | David Chiron | Received |
264-P | Preclinical evaluation of the novel pleiotropic BCR kinase inhibitor IQS019 in in vitro and in vivo models of B lymphoid neoplasms | Gael Roue | Received |
266-P | Transcriptomic profiling of response to PI3K inhibition by BKM120 in non-Hodgkin lymphoma (NHL) and Hodgkin lymphoma (HL) | Micheal Coyle | Received |
267-P | Differential expression of PI3K isoforms/PTEN in follicular lymphoma and diffuse large B-cell lymphoma - therapeutic implications | Lim Soon Thye | Received |
268-P | Inhibition of both PI3Ka and PI3Kd by Copanlisib is essential to attenuate both BCR-dependent and BCR-independent activation of NF&954;B and proliferation in DLBCL cells | Juliane Paul | Received |
269-P | Pre-clinical lymphoma models show high sensitivity to the small molecule YK-4-279 | Elaine Chung | Received |
271-P | The BET bromodomain inhibitor OTX015 (MK-8628) affects the expression of microRNAs involved in the pathogenesis of lymphoma: in vitro and in vivo evidence | Afua Adjeiwaa Mensah | Received |
272-P | OTX015 (MK-8628) targets genes with high levels of promoter H3K4me3 involved in key signalling pathways in splenic marginal zone lymphoma and mantle cell lymphoma | Chiara Tarantelli | Received |
273-P | Pixantrone has pre-clinical synergistic activity when combined with targeted agents in diffuse large B-cell lymphoma. | Chiara Tarantelli | Received |
274-P | Novel CD37-Targeting Antibody-Drug Conjugate (ADC), IMGN529, Has Synergistic Activity in Combination with Rituximab in Non-Hodgkin Lymphoma (NHL) Models | Angela Romanelli | Received |
275-P | A variant of obinutuzumab with abolished ADCC, ADCP and CDC is as efficient as rituximab in B cell depletion and antitumor activity | Christian Klein | Received |
277-P | Targeting the MUC1-C oncoprotein is associated with downregulation of TIGAR and ROS-mediated cutaneous T-cell lymphoma cell death | Salvia Jain | Received |
278-P | MYC and CHK1 Dependent Cell Death in T-cell Lymphoma and Hodgkin Lymphoma Cells and Human Xenograft Models With Anti-Proteasomal Therapy | Andrew Evens | Received |
279-P | Alisertib Exhibits Broad Activity And Selectively Synergizes With Romidepsin In Preclinical Models Of T-Cell Lymphoma | Kelly Zullo | Received |
280-P | Interim Analysis of a Phase 1b Study Evaluating the Safety of GS-9820, a Second-Generation PI3Kd-Inhibitor, in Relapsed/Refractory Lymphoid Malignancies | Arnon Kater | Received |
282-P | Everolimus plus R-CHOP as initial therapy for DLBCL: a phase I/feasibility study (NCCTG N1085 Alliance) | Patrick Johnston | Received |
283-P | Safety and clinical activity of Temsirolimus in combination with Rituximab and DHAP for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma | Mathias Witzens-Harig | Received |
286-P | Phase I dose-escalation study of BI 836826 in patients (pts) with relapsed or refractory non-Hodgkin lymphoma (NHL) of B cell origin | Janet Lightwood | Received |
Digital Object Identifier. Official code used to identify documents published on internet; similar to ISBN for books. You may use this code to reference your poster in future scientific publications or CVs. It can be found from anywhere in the world. To find the poster page, log onto www.medra.org and enter the DOI, or enter in your internet browser https://dx.doi.org/ followed by the DOI string asigned to your congress. |
||||
|